Literature DB >> 23369095

IDO⁺ DCs and signalling pathways.

Yue Wang1, Bao-Hong Yang, Hui Li, Shui Cao, Xiu-Bao Ren, Jin-Pu Yu.   

Abstract

Dendritic cells (DCs) have traditionally been viewed as constituting an 'information management' system that functions solely to integrate a diverse array of incoming signals, in order to induce immune reactivity. In recent years, however, there has been a shift towards viewing these cells as key regulators in the orchestration of immunological tolerance, with increasing recognition that they are capable of suppressing T-cell responses depending on signalling processes and localised biochemical conditions. Indoleamine 2,3-dioxygenase (IDO) competent (IDO⁺) DCs are a subset of human DCs which are programmed to a tolerogenic state and play a vital role in establishing and maintaining a tumour-suppressing milieu. The expression of IDO in these DCs represents a key mechanism responsible for inducing the tolerogenic state. However, the mechanisms by which IDO becomes dysregulated in this subset of DCs have not yet been described. In this review, the function of IDO⁺ DCs within the cancer-tolerogenic milieu, as well as the signals responsible for expression of IDO in this subset, will be discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23369095     DOI: 10.2174/15680096113139990073

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  8 in total

1.  Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer.

Authors:  Jinpu Yu; Yue Wang; Fang Yan; Peng Zhang; Hui Li; Hua Zhao; Cihui Yan; Fan Yan; Xiubao Ren
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

2.  Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.

Authors:  Tengfei Wei; Jun Zhang; Yanghua Qin; Yu Wu; Li Zhu; Longkun Lu; Gusheng Tang; Qian Shen
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

3.  Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.

Authors:  Maria Letícia Baptista Salvadori; Pedro Kastein Faria da Cunha Bianchi; Luiz Henrique Gebrim; Renata Santos Silva; José Roberto Kfoury
Journal:  Med Oncol       Date:  2015-10-06       Impact factor: 3.064

4.  Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression- and autoimmunity-associated genes.

Authors:  Pilvi Maliniemi; Sonja Hahtola; Kristian Ovaska; Leila Jeskanen; Liisa Väkevä; Kirsi Jäntti; Rudolf Stadler; David Michonneau; Sylvie Fraitag; Sampsa Hautaniemi; Annamari Ranki
Journal:  Orphanet J Rare Dis       Date:  2014-11-12       Impact factor: 4.123

5.  Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis.

Authors:  Ya-Ling Hsu; Jen-Yu Hung; Shin-Yi Chiang; Shu-Fang Jian; Cheng-Ying Wu; Yi-Shiuan Lin; Ying-Ming Tsai; Shah-Hwa Chou; Ming-Ju Tsai; Po-Lin Kuo
Journal:  Oncotarget       Date:  2016-05-10

Review 6.  Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer.

Authors:  Enrica Marmonti; Jacqueline Oliva-Ramirez; Cara Haymaker
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

Review 7.  Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy.

Authors:  Inès Dufait; Els Van Valckenborgh; Eline Menu; David Escors; Mark De Ridder; Karine Breckpot
Journal:  Oncotarget       Date:  2016-07-05

Review 8.  Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy.

Authors:  Milena Perrone; Giovanna Talarico; Claudia Chiodoni; Sabina Sangaletti
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.